PML is a rare but serious infection of the central nervous system (CNS). The Progressive Multifocal Leukoencephalopathy (PML) Consortium is a joint effort between Biogen Idec, Pfizer, MedImmune and Roche intended to find methods to enable prediction and prevention of PML associated with immunomodulatory and immunosuppressive treatments.
Save the Date for 2015 Research Conference
The PML Consortium will hold a research conference on PML on August 25-26, 2015 at AstraZeneca in Mölndal, Sweden. More information is forthcoming.
Registration will open in February 2015.